CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2012--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
developing Toll-like receptor targeted product candidates for the
treatment of autoimmune diseases and as vaccine adjuvants, today
announced that its management will present a company overview at the
24th Annual Piper Jaffray Healthcare Conference in New York, NY. The
presentation will take place on Wednesday, November 28, 2012 at 9:00
a.m. ET.
A live audio webcast of the presentation will be available in the
Investor section of Idera's website: www.iderapharma.com.
An archived version will also be available on the Company's website
after the event for a limited time.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR)
drug discovery platform to create immunomodulatory drug candidates and
has a clinical development program in autoimmune diseases. Additionally,
Idera has a collaboration with Merck & Co. for the use of TLR-targeted
candidates as vaccine adjuvants for cancer, infectious diseases and
Alzheimer’s disease. The Company is also advancing its gene-silencing
oligonucleotide (GSO) technology for the purpose of inhibiting the
expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties.
For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should,"
"could," "will," "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause Idera's actual results to differ materially from those
indicated by such forward-looking statements, including whether Idera’s
cash resources will be sufficient to fund the Company’s continuing
operations and the further development of the Company’s autoimmune
disease program; whether results obtained in preclinical studies and
early clinical trials, such as the results from the preclinical studies
referred to in this release, will be indicative of results obtained in
future clinical trials; whether products based on Idera's technology
will advance into or through the clinical trial process on a timely
basis or at all and receive approval from the United States Food and
Drug Administration or equivalent foreign regulatory agencies; whether,
if the Company's products receive approval, they will be successfully
distributed and marketed; whether the Company will be able to license
any of its TLR target candidates on a timely basis or at all; whether
the Company's collaboration with Merck & Co, Inc., will be successful;
whether the patents and patent applications owned or licensed by the
Company will protect the Company's technology and prevent others from
infringing it; and such other important factors as are set forth under
the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2012 which important factors are
incorporated herein by reference. Idera disclaims any intention or
obligation to update any forward-looking statements.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com